Gilad Shabtai Net Worth

The estimated Net Worth of Gilad Shabtai is at least $2.01 Tisíc dollars as of 30 April 2018. Gilad Shabtai owns over 75,000 units of Eloxx Pharmaceuticals Inc stock worth over $2,011 and over the last 7 years Gilad sold ELOX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Gilad Shabtai ELOX stock SEC Form 4 insiders trading

Gilad has made over 3 trades of the Eloxx Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Gilad bought 75,000 units of ELOX stock worth $731,250 on 30 April 2018.

The largest trade Gilad's ever made was buying 75,000 units of Eloxx Pharmaceuticals Inc stock on 30 April 2018 worth over $731,250. On average, Gilad trades about 29,267 units every 11 days since 2018. As of 30 April 2018 Gilad still owns at least 3,351,770 units of Eloxx Pharmaceuticals Inc stock.

You can see the complete history of Gilad Shabtai stock trades at the bottom of the page.

What's Gilad Shabtai's mailing address?

Gilad's mailing address filed with the SEC is C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, 4TH FLOOR NORTH, WALTHAM, MA, 02451.

Insiders trading at Eloxx Pharmaceuticals Inc

Over the last 7 years, insiders at Eloxx Pharmaceuticals Inc have traded over $0 worth of Eloxx Pharmaceuticals Inc stock and bought 22,391,804 units worth $47,296,070 . The most active insiders traders include Ran Nussbaum, Tomer Kariv a Steven D Rubin. On average, Eloxx Pharmaceuticals Inc executives and independent directors trade stock every 26 days with the average trade being worth of $275. The most recent stock trade was executed by Alan Edmund Walts on 1 December 2021, trading 37,695 units of ELOX stock currently worth $23.

What does Eloxx Pharmaceuticals Inc do?

eloxx pharmaceuticals, inc. is a clinical-stage biopharmaceutical company developing novel rna-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. premature stop codons are point mutations that disrupt protein synthesis from messenger rna. as a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. these premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. read-through therapeutic development is focused on extending mrna half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. eloxx’s lead product candidate, elx-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. elx-02 is in the early stages of clin

Complete history of Gilad Shabtai stock trades at Eloxx Pharmaceuticals Inc

Eloxx Pharmaceuticals Inc executives and stock owners

Eloxx Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Gregory Williams,
  Chief Executive Officer, Director
• Martijn Kleijwegt,
  Independent Director
• Steven Rubin,
  Independent Director
• Ran Nussbaum,
  Independent Director
• Zafrira Avnur,
  Independent Director
• Jasbir Seehra,
  Independent Director
• Gadi Veinrib,
  Independent Director
• Tomer Kariv,
  Independent Chairman of the Board
• Silvia Noiman,
  Director
• Stephen MacDonald,
  Principal Accounting Officer, Vice President - Finance and Accounting, Treasurer
• Neil Belloff,
  Chief Operating Officer, General Counsel, Corporate Secretary
• Matthew Goddeeris Ph.D.,
  VP of Research
• Dr. Ali Hariri M.D.,
  Chief Medical Officer
• Dr. Vijay Modur MBBS, Ph.D.,
  Head of R&D
• Rose Villandry,
  VP of HR
• Barbara Ryan,
  Investor Relations Officer
• Daniel E. Geffken M.B.A., MBA,
  Interim CFO, Principal Financial Officer & Principal Accounting Officer
• Sumit Aggarwal M.B.A.,
  Pres, CEO & Director
• David P. Snow,
  
• Robert Ward,
  
• Management 4 G.P. (2015) Lt...,
  
• Management 4 G.P. (2015) Lt...,
  
• Management Iii G.P. (2011) ...,
  
• Gilad Shabtai,
  10% owner
• Management 4 G.P. (2015) Lt...,
  
• Gregory L Weaver,
  
• Sumit Aggarwal,
  PRESIDENT AND CEO
• Vijay Modur,
  HEAD OF R&D
• Rajesh B Parekh,
  Director
• Daniel E. Geffken,
  INTERIM CFO
• Lindsay Androski,
  Director
• Alan Edmund Walts,
  Director